You are here: Industry Insights > Roche

News List

Roche's Tecentriq shows promise in early triple-negative breast cancer pharmatimes
June 22, 2020
Roche's Tecentriq (atezolizumab) in combination with chemotherapy has improved treatment response in people with early triple-negative breast cancer (TNBC), raising hopes for a new therapeutic option for the condition.
Cipla and Roche partner up to improve access to oncology medicines expresspharma
June 19, 2020
Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.
Roche partners with Entero Healthcare Solutions for nephrology medicines expresspharma
June 19, 2020
Roche Products stated that it is expanding its presence in different states in India by increasing its field force in a phased manner and investing in new talent in India over the next few months.
Final NHS green light for Roche's Kadcyla pharmatimes
June 11, 2020
NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer.
Innovent Biologics enters drug development deal with Roche pharmaceutical-technology
June 10, 2020
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
Roche's Tecentriq/Avastin combo wins US approval pharmatimes
June 04, 2020
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer.
Roche to begin Covid-19 pneumonia trial with Actemra/RoActemra plus remdesivir pharmaceutical-business-review
June 02, 2020
Roche has announced the commencement of phase III clinical study of Actemra/RoActemra plus remdesivir in hospitalised patients with severe Covid-19 pneumonia.
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patien worldpharmanews
June 01, 2020
Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir ...
NICE u-turn backs Roche's Tecentriq for small-cell lung cancer pharmatimes
May 29, 2020
A combination of Roche's Tecentriq (atezolizumab), carboplatin and etoposide has now been recommended as an NHS-funded option for untreated extensive-stage small-cell lung cancer (ES-SCLC), following an earlier rejection by cost regulators.
Roche Initiates Phase III Trial in COVID-19 Pneumonia contractpharma
May 29, 2020
To evaluate Actemra/RoActemra plus remdesivir in hospitalized patients with severe Pneumonia.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page